RS4-CLINICALLY IMPORTANT FACTORS CONTRIBUTING TO COSTS OF CARE DEFINED VIA ANALYSIS OF COMPREHSIVE PATIENT RECORDS
Palmu PJ¹, Reissell E¹, Schultz J¹, Rehn M¹, Pirskanen A¹, Minkkinen S¹, Salonoja M¹, Kunnas T¹, Sintonen H², Haahtela T3, Lindqvist A³, Laitinen T^1
1GeneOS Ltd, Helsinki, Finland, ²University of Helsinki, Helsinki, Finland, ³Helsinki University Hospital, Helsinki, Finland

ES2-DIRECT MEDICAL COSTS OF SOLID ORGAN TRANSPLANT IN BRITISH COLUMBIA, CANADA
Levy AR1, Sobolev B², James D³, Sullivan SD⁴, Partovi N⁵, Barrable W⁵, Levy R⁵
1Oxford Outcomes Ltd, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³St Paul's Hospital, Vancouver, BC, Canada, ⁴University of Washington, Seattle, WA, USA, ⁵BC Transplant Society, Vancouver, BC, Canada

Best New Investigator Podium Presentations

RS3-THE COST-EFFECTIVENESS OF TIOTROPIUM VERSUS IPRATROPIUM IN A US VETERANS POPULATION DIAGNOSED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Akobundu E¹, DeLisle S², Giangreco G³, Mullins CD^1
1University of Maryland School of Pharmacy, Baltimore, MD, USA, ²University of Maryland School of Medicine and VA Maryland Health Care System, Baltimore, MD, USA, ³VA Maryland Health Care System, Baltimore, MD, USA

GI3-COST-UTILITY ANALYSIS IN A UK SETTING OF VASOACTIVE DRUG TREATMENTS IN ACUTE BLEEDING OESOPHA
Wechowski JG¹, Tetlow AP¹, McEwan P¹, Woehl A¹, Currie CJ^2
1Cardiff Research Consortium, Cardiff, South Glamorgan, UK, ²Cardiff University, Cardiff, South Glamorgan, UK

CV7-RESOURCE UTILIZATION AND COSTS FOLLOWING HOSPITAL INPATIENT ADMISSION FOR CONGESTIVE HEART FAILURE
Gemmen EK¹, Bharmal M¹, Zyczynski T^2
1Quintiles Strategic Research Services, Falls Church, VA, USA, ²GE Healthcare, Princeton, NJ, USA

Best Student Podium Presentations

MC6-HOW DO THE SCORES OF GENERIC HRQOL INSTRUMENTS REFLECT THE DIRECT TTO VALUATIONS OF OWN HEALTH BY GENERAL POPULATION?
Kotomäki T, Honkalampi T, Sintonen H
University of Helsinki, Helsinki, Finland

IN3-RELATIONSHIP BETWEEN ADHERENCE TO ANTIRETROVIRAL THERAPY AND THE COST-EFFECTIVENESS OF ANTIRETROVIRAL THERAPY
Habib MJ¹, Lawson K², Summers KK³, Eakin RT², Barner J², Brown C², Shepherd MD^2
1i3 Innovus, Burlington, ON, Canada, ²University of Texas at Austin, Austin, TX, USA, ³South Texas Veterans Health Care System, San Antonio, TX, USA

IN4 MEDICAL MANAGEMENT AND COSTS ASSOCIATED WITH STAPHYLOCOCCUS AUREUS (SA) BACTERAEMIA IN HAEMODIALYSIS PATIENTS: A COST-OF-ILLNESS STUDY
Strens D¹, Moeremans K¹, Annemans L¹, Jadoul M², Cambier P³, Billiouw JM^4
1IMS HEOR, Brussels, Belgium, ²Cliniques Universitaires St Luc, Brussels, Belgium, ³CHR Citadelle, Liège, Belgium, ⁴O.l.Vrouwziekenhuis Aalst, Aalst, Belgium

ISPOR Best Contributed Poster Presentation Awards

Best General Poster Presentations

PDB7-THE RELATIVE COST EFFECTIVENESS OF INSULIN GLARGINE VERSUS NPH INSULIN IN THE UK IN PEOPLE WITH TYPE 1 DIABETES
McEwan P¹ , Poole CD², Holmes P3, Tetlow AP², Currie CJ^1
1Cardiff University, Cardiff, South Glamorgan, UK, ²Cardiff Research Consortium, Cardiff, South Glamorgan, UK, 3sanofi-aventis UK, Guildford, Surrey, UK

PAR4-HEALTHCARE UTILIZATION AND COSTS ASSOCIATED WITH BLUNT AND PENETRATING TRAUMA IN A UNITED STATES MANAGED CARE POPULATION
Candrilli SD¹, Davis KL¹, Joshi AV², Tortella BJ^2
1RTI Health Solutions, Research Triangle Park, NC, USA, ²Novo Nordisk, Inc, Princeton, NJ, USA

PMH46-ASSESSING THE CROSS-CULTURAL COMPARABILITY OF THE CENTRE FOR EPIDEMIOLOGIC STUDIES DEPRESSION SCALE (CES-D)
Meads DM, McKenna SP, Doward LC
Galen Research, Manchester, UK

Best New Investigator Poster Presentations

PCV59-LIPID TESTING AMONG PATIENTS RECEIVING FIRST-EVER STATIN THERAPY IN UK GENERAL PRACTICES
Phatak H¹, Wentworth C², Burke TA^3
1Rutgers University: The State University of New Jersey, Piscataway, NJ, USA, ²Analytic Consulting Solutions, Wakefield, RI, USA, ³ Merck & Co., Inc, Whitehouse Station, NJ, USA

PDB40-HEALTH-RELATED QUALITY OF LIFE OF TYPE 2 DIABETICS IN GERMAN PRIMARY CARE: RESULTS OF THE DETECT STUDY
Pieper L¹, Klotsche J¹, Jacobi F¹, Pittrow D¹, Böhler S¹, Lehnert H², Wittchen HU^1
1Technische Universität Dresden, Dresden, Germany, ²University of Warwick, Coventry, UK

PUK14-A COST-UTILITY ANALYSIS IN A UK SETTING OF CINACALCET FOR SECONDARY HYPERPARATHYROIDISM IN END STAGE RENAL DISEASE
Mealing SJ¹, Garside R¹, Pitt M1, Anderson R¹, D'Sousa R², Stein K^1
1Peninsula Medical School, Exeter, Devon, England, ²Royal Devon and Exeter Hospital, Exeter, Devon, England

Best Student Poster Presentations

PAR8-TRENDS IN PRESCRIPTION CLAIMS FOLLOWING THE WITHDRAWAL OF ROFECOXIB FROM THE CANADIAN MARKET
Desjardins O¹, Manley J¹, Nanwa N¹, Goh YI2, Smith RW¹, Einarson TR^1
1University of Toronto, Toronto, ON, Canada, 2Hospital for Sick Children, Toronto, ON, Canada

PMH24-INCREASING FORMULARY ACCESS TO INNOVATIVE DRUGS: DIFFERENCES FOR TREATING SCHIZOPHRENIA IN A MEDI-CAL POPULATIONPOS14-QUALITY OF LIFE ACCORDING TO EQ-5D AFTER OSTEOPOROTIC HIP FRACTURE IN POLAND
Golicki D¹, Sliwka A¹, Fijewski G², Latek M^{3  
1}Medical University of Warsaw, Warsaw, Poland, ²Medical University of Warsaw, Department of Orthopaedics and Traumatology of Locomotor System, Warsaw, Poland, ³ Warsaw School of Economics, Warszawa, Poland

PMC2-EFFICIENT DATA MINING AND PROBABILISTIC INFERENCE WITH P-COURSE: A BAYESIAN METHOD WITH MULTILEVEL PRIORS FOR MEDICAL APPLICATIONS
Soini EJ¹, Martikainen JA², Lahtinen J³ , Myllymäki P³ , Kontkanen P³ , Valtonen H⁴, Ryynänen OP^{5 1}Department of Health Policy and Management, Department of Social Pharmacy, University of Kuopio, Kuopio, Finland, ²Centre for Pharmaceutical Policy and Economics (CEPPE), Department of Social Pharmacy, University of Kuopio, Kuopio, Finland, ³ Complex Systems Computation Research Group (CoSCo), Helsinki Institute for Information Technology (HIIT), University of Helsinki, Helsinki, Finland, ⁴Department of Health Policy and Management, University of Kuopio, Kuopio, Finland, ⁵General Practice, Department of Public Health and Clinical Nutrition, University of Kuopio, Kuopio, Finland